Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors


The invention relates to compounds that inhibit HIV-1 DNA synthesis mediated by reverse transcriptase (RT). HIV-1 DNA synthesis by RT utilizes deoxynucleoside 5’-triphosphate (dNTP) as substrate and like many other enzymes, the reaction is reversible. Pyrophosphate analogs like imidodiphosphate strongly promote reverse reaction dNTP products containing the imidodiphosphate group instead of the naturally occurring pyrophosphate group. This imidodiphosphate-containing dNTP was found to be a potent inhibitor of the forward RT reaction. Whereas pyrophosphorolysis is limited by a nonchemical step, replacing the bridging oxygen of pyrophosphate with an imido group resulted in a change in the rate-limiting step, so that the imidodiphosphate-dependent reverse reaction was limited by chemistry. There exists, then, the potential to use pyrophosphate analogs therapeutically.

Potential Commercial Applications: Competitive Advantages:
  • Anti-microbial
  • HIV therapeutic
 


Inventors:

Samuel Wilson (NIEHS)  ➽ more inventions...

William Beard (NIEHS)  ➽ more inventions...

David Shock (NIEHS)  ➽ more inventions...


Intellectual Property:
US Application No. 62/542,600

Collaboration Opportunity:

The National Institute of Environmental Health Sciences seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate this technology. Please contact Sally E. Tilotta, PhD, Director, Office of Technology Transfer, National Institute of Environmental Health Sciences; Phone: (919) 316-4526; Email: sally.tilotta@nih.gov.


Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-210-2017/0
Updated: Aug 23, 2017